{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:47:57Z","timestamp":1792759677660,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16K10148"],"award-info":[{"award-number":["16K10148"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jid.2019.01.007","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T02:43:36Z","timestamp":1548297816000},"page":"1490-1496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti\u2013PD-1 Therapy"],"prefix":"10.1016","volume":"139","author":[{"given":"Takashi","family":"Inozume","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Yaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ariyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Togashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Ohnuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Honobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuyoshi","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2019.01.007_bib1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune escape mechanisms as a guide for cancer immunotherapy","volume":"21","author":"Beatty","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2019.01.007_bib2","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-16-3172","article-title":"Acquired immune resistance follows complete tumor regression without loss of target antigens or IFNgamma signaling","volume":"77","author":"Donia","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2019.01.007_bib3","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2019.01.007_bib4","first-page":"956","article-title":"Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells","volume":"33","author":"Inozume","year":"2010","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.jid.2019.01.007_bib5","first-page":"109","article-title":"IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells","volume":"32","author":"Inozume","year":"2009","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.jid.2019.01.007_bib6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ijc.20735","article-title":"Novel melanoma antigen, FCRL\/FREB, identified by cDNA profile comparison using DNA chip are immunogenic in multiple melanoma patients","volume":"114","author":"Inozume","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jid.2019.01.007_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/JID.2015.404","article-title":"Melanoma cells control antimelanoma CTL responses via interaction between TIGIT and CD155 in the effector phase","volume":"136","author":"Inozume","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2019.01.007_bib8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","article-title":"TIGIT: a key inhibitor of the cancer immunity cycle","volume":"38","author":"Manieri","year":"2017","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jid.2019.01.007_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.coi.2017.01.003","article-title":"Targeting NK-cell checkpoints for cancer immunotherapy","volume":"45","author":"Muntasell","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jid.2019.01.007_bib10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.tibtech.2011.04.009","article-title":"Treating cancer with genetically engineered T cells","volume":"29","author":"Park","year":"2011","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.jid.2019.01.007_bib11","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jid.2019.01.007_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/annonc\/mdw534","article-title":"Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies","volume":"28","author":"Salama","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jid.2019.01.007_bib13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jid.2019.01.007_bib14","doi-asserted-by":"crossref","first-page":"17858","DOI":"10.1073\/pnas.0903474106","article-title":"The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity","volume":"106","author":"Stanietsky","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2019.01.007_bib15","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.3389\/fimmu.2017.01934","article-title":"New chimeric antigen receptor design for solid tumors","volume":"8","author":"Wang","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2019.01.007_bib16","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2019.01.007_bib17","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.1158\/1078-0432.CCR-15-0420","article-title":"Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy","volume":"21","author":"Zhai","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X19300235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X19300235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:14:12Z","timestamp":1758302052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X19300235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0022202X19300235"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2019.01.007","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti\u2013PD-1 Therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2019.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}